Permeability barrier disorder in Niemann-Pick disease: Sphingomyelin-ceramide processing required for normal barrier homeostasis

被引:120
作者
Schmuth, M
Man, MQ
Weber, F
Gao, WN
Feingold, KR
Fritsch, P
Elias, PM
Holleran, WM
机构
[1] Univ Calif San Francisco, Sch Med, Dept Dermatol, Dermatol Serv, San Francisco, CA 94121 USA
[2] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA
[4] Vet Affairs Med Ctr, Dermatol Serv, San Francisco, CA 94121 USA
[5] Vet Affairs Med Ctr, Res Unit, San Francisco, CA 94121 USA
[6] Univ Innsbruck, Dept Dermatol, A-6020 Innsbruck, Austria
关键词
ceramides; epidermis; glucosylceramides; sphingomyelin; sphingomyelinase; stratum corneum; transepidermal water loss;
D O I
10.1046/j.1523-1747.2000.00081.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Prior studies have established the requirement for enzymatic hydrolysis of glucosylceramides to ceramide for epidermal barrier homeostasis. In this study, we asked whether sphingomyelin-derived ceramide, resulting from acid-sphingomyelinase activity, is also required for normal barrier function. We showed first, that a subset of Niemann-Pick patients with severe acid-sphingomyelinase deficiency (i.e., <2% residual activity) demonstrate abnormal permeability barrier homeostasis, i.e., delayed recovery kinetics following acute barrier disruption by cellophane tape-stripping. To obtain further mechanistic insights into the potential requirement for sphingomyelin-to-ceramide processing for the barrier, we next studied the role of acid-sphingomyelinase in hairless mouse skin. Murine epidermis contains abundant acid-sphingomyelinase activity (optimal pH 5.1-5.6). Two hours following acute barrier disruption by tape-stripping, acid-sphingomyelinase activity increases 1.44-fold (p<0.008 versus vehicle-treated controls), an increase that is blocked by a single topical application of the acid-sphingomyelinase inhibitor, palmitoyldihydrosphingosine. Furthermore, both palmitoyldihydrosphingosine and desipramine, a chemically and mechanically unrelated acid-sphingomyelinase inhibitor, significantly delay barrier recovery both 2 and 4 h after acute barrier abrogation. Inhibitor application also causes both an increase in sphingomyelin content, and a reduction of normal extracellular lamellar membrane structures, in the stratum corneum. Both of the inhibitor-induced delays in barrier recovery can be overridden by co-applications of topical ceramide, demonstrating that an alteration of the ceramide-sphingomyelin ratio, rather than sphingomyelin accumulation, is likely responsible for the barrier abnormalities that occur with acid-sphingomyelinase deficiency. These studies demonstrate an important role for enzymatic processing of sphingomyelin-to-ceramide by acid-sphingomyelinase as a mechanism for generating a portion of the stratum corneum ceramides for permeability barrier homeostasis in mammalian skin.
引用
收藏
页码:459 / 466
页数:8
相关论文
共 75 条
[1]  
BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
[2]   SPHINGOMYELINASE IN PIG AND HUMAN EPIDERMIS [J].
BOWSER, PA ;
GRAY, GM .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1978, 70 (06) :331-335
[3]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[4]  
Chujor CSN, 1998, J LIPID RES, V39, P277
[5]   NIEMANN-PICK DISEASE - A REVIEW OF 18 PATIENTS [J].
CROCKER, AC ;
FARBER, S .
MEDICINE, 1958, 37 (01) :1-95
[6]   LOCALIZATION AND COMPOSITION OF LIPIDS IN NEONATAL MOUSE STRATUM GRANULOSUM AND STRATUM-CORNEUM [J].
ELIAS, PM ;
BROWN, BE ;
FRITSCH, P ;
GOERKE, J ;
GRAY, GM ;
WHITE, RJ .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1979, 73 (05) :339-348
[7]   MEMBRANE STRUCTURAL ALTERATIONS IN MURINE STRATUM-CORNEUM - RELATIONSHIP TO THE LOCALIZATION OF POLAR LIPIDS AND PHOSPHOLIPASES [J].
ELIAS, PM ;
MENON, GK ;
GRAYSON, S ;
BROWN, BE .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1988, 91 (01) :3-10
[8]  
ELIAS PM, 1991, ADV LIPID RES, V24, P1
[9]   MOLECULAR-BASIS OF ACID SPHINGOMYELINASE DEFICIENCY IN A PATIENT WITH NIEMANN-PICK DISEASE TYPE-A [J].
FERLINZ, K ;
HURWITZ, R ;
SANDHOFF, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 179 (03) :1187-1191
[10]  
FERLINZ K, 1995, AM J HUM GENET, V56, P1343